8-K Announcements
6Material company update
Mar 12, 2026·SEC
Material company update
Mar 9, 2026·SEC
Material company update
Jan 27, 2026·SEC
Korro Bio, Inc.(KRRO)Earnings, Financials & Key Ratios
KRRO•NASDAQ
$13.34
$125M mkt cap·Price updated May 6, 2026
AboutKorro Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases. Korro Bio, Inc. is based in Cambridge, Massachusetts.Show more
- Revenue$6M+181.5%
- EBITDA-$83M+6.0%
- Net Income-$117M-40.3%
- EPS (Diluted)-12.48-33.2%
- Gross Margin33.04%-67.0%
- EBITDA Margin-1299.47%+66.6%
- Operating Margin-1366.43%+66.2%
- Net Margin-1834.48%+50.2%
- ROE-110.7%-118.8%
- ROIC-58.85%+20.4%
- Debt/Equity0.85+202.9%
KRRO Key Insights
Korro Bio, Inc. (KRRO) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
No significant strengths identified
✗Weaknesses
- ✗Profits declining 34.6% over 5 years
- ✗Weak Piotroski F-Score: 2/9
- ✗Negative free cash flow
- ✗Sales declining 29.6% over 5 years
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
KRRO Price & Volume
Korro Bio, Inc. (KRRO) stock price & volume — 10-year historical chart
Loading chart...
KRRO Growth Metrics
Korro Bio, Inc. (KRRO) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-29.61%
3 Years-
TTM181.46%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-40.29%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-32.91%
Return on Capital
10 Years-49.4%
5 Years-50.75%
3 Years-54.52%
Last Year-55.84%
KRRO Recent Earnings
Korro Bio, Inc. (KRRO) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 6/12 qtrs (50%)●Beat Revenue 4/12 qtrs (100%)
Q2 2026Latest
Mar 12, 2026EPS
$5.32
Est $1.93
-175.6%
Revenue
$1M
Est $700,000
+85.7%
Q4 2025
Nov 12, 2025EPS
$1.92
Est $2.61
+26.4%
Revenue
$1M
Est $425,000
+156.5%
Q3 2025
Aug 12, 2025EPS
$2.74
Est $2.54
-7.9%
Revenue
$1M
Est $320,780
+355.1%
Q2 2025
May 7, 2025EPS
$2.49
Est $2.60
+4.2%
Revenue
$3M
Est $426,900
+497.3%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Mar 12, 2026 | $5.32vs $1.93-175.6% | $1Mvs $700,000+85.7% |
| Q4 2025 | Nov 12, 2025 | $1.92vs $2.61+26.4% | $1Mvs $425,000+156.5% |
| Q3 2025 | Aug 12, 2025 | $2.74vs $2.54-7.9% | $1Mvs $320,780+355.1% |
| Q2 2025 | May 7, 2025 | $2.49vs $2.60+4.2% | $3Mvs $426,900+497.3% |
Based on last 12 quarters of dataView full earnings history →
KRRO Peer Comparison
Korro Bio, Inc. (KRRO) competitors in RNA and Genome Editing Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 BEAM | 3.32B | 32.33 | -39.92 | 120.01% | -57.24% | -7.31% | 0.24 | |
 EDIT | 310.73M | 3.18 | -1.76 | -100% | -5.23% | 0.66 | ||
 CRSP | 5.31B | 55.08 | -8.51 | -89.97% | -138.57% | -30.88% | 0.21 | |
 NTLA | 1.61B | 13.85 | -3.64 | -100% | -61.47% | 0.14 | ||
 PRME | 615.68M | 3.41 | -2.53 | 55.28% | -43.42% | -178.61% | 0.96 | |
 RCKT | 418.11M | 3.86 | -1.92 | -80.49% | 0.09 | |||
 FATE | 264.17M | 2.29 | -1.99 | -51.24% | -20.51% | -65.79% | 0.38 | |
 ILMN | 21.66B | 142.58 | 26.16 | -0.78% | 19.43% | 32.84% | 0.94 |
Compare KRRO vs Peers
Korro Bio, Inc. (KRRO) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
KRRO Income Statement
Korro Bio, Inc. (KRRO) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 28.95M | 36.98M | 14.07M | 0 | 0 | 2.27M | 6.39M |
| Revenue Growth % | - | - | - | 27.76% | -61.96% | -100% | - | - | 181.46% |
| Cost of Goods Sold | 531K | 654K | 16.81M | 1.58M | 3.84M | 0 | 0 | 0 | 4.28M |
| COGS % of Revenue | - | - | 58.08% | 4.27% | 27.3% | - | - | - | 66.96% |
| Gross Profit | -531K▲ 0% | -654K▼ 23.2% | 12.13M▲ 1955.4% | 35.4M▲ 191.8% | 10.23M▼ 71.1% | 0▼ 100.0% | 0▲ 0% | 2.27M▲ 0% | 2.11M▼ 7.0% |
| Gross Margin % | - | - | 41.92% | 95.73% | 72.7% | - | - | 100% | 33.04% |
| Gross Profit Growth % | - | -23.16% | 1955.35% | 191.78% | -71.11% | -100% | - | - | -7% |
| Operating Expenses | 15.78M | 18.29M | 32.81M | 62.95M | 94.26M | 59M | 84.53M | 94.18M | 89.45M |
| OpEx % of Revenue | - | - | 113.34% | 170.22% | 670.02% | - | - | 4147.12% | 1399.47% |
| Selling, General & Admin | 3.99M | 6.71M | 14.47M | 26.3M | 34.93M | 16.8M | 36.54M | 30.55M | 28.16M |
| SG&A % of Revenue | - | - | 50.01% | 71.11% | 248.32% | - | - | 1345% | 440.54% |
| Research & Development | 11.79M | 11.58M | 18.33M | 36.66M | 59.32M | 42.2M | 57.25M | 63.64M | 65.58M |
| R&D % of Revenue | - | - | 63.34% | 99.11% | 421.69% | - | - | 2802.11% | 1025.89% |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | -9.25M | 0 | -4.28M |
| Operating Income | -16.31M▲ 0% | -18.94M▼ 16.2% | -20.68M▼ 9.1% | -27.55M▼ 33.3% | -84.03M▼ 205.0% | -59M▲ 29.8% | -84.53M▼ 43.3% | -91.91M▼ 8.7% | -87.34M▲ 5.0% |
| Operating Margin % | - | - | -71.42% | -74.49% | -597.32% | - | - | -4047.12% | -1366.43% |
| Operating Income Growth % | - | -16.18% | -9.14% | -33.25% | -205.01% | 29.79% | -43.28% | -8.73% | 4.97% |
| EBITDA | -15.78M | -18.29M | -19.86M | -25.97M | -80.19M | -56.49M | -80.9M | -88.34M | -83.06M |
| EBITDA Margin % | - | - | -68.62% | -70.22% | -570.02% | - | - | -3890.14% | -1299.47% |
| EBITDA Growth % | - | -15.94% | -8.59% | -30.75% | -208.78% | 29.56% | -43.23% | -9.2% | 5.98% |
| D&A (Non-Cash Add-back) | 531K | 654K | 813K | 1.58M | 3.84M | 2.51M | 3.63M | 3.56M | 4.28M |
| EBIT | -20.06M | -19.06M | -18.75M | -26.48M | -83.91M | -59M | -84.53M | -91.91M | -87.34M |
| Net Interest Income | 0 | 0 | 1.78M | 994K | -367K | 829K | 0 | 0 | 0 |
| Interest Income | 0 | 0 | 1.78M | 994K | 397K | 947K | 0 | 0 | 0 |
| Interest Expense | 174K | 106K | 0 | 0 | 764K | 118K | 0 | 0 | 0 |
| Other Income/Expense | -3.93M | -224K | 1.93M | 1.07M | -640K | 976K | 3.39M | 8.47M | -29.28M |
| Pretax Income | -20.24M▲ 0% | -19.17M▲ 5.3% | -18.75M▲ 2.2% | -26.48M▼ 41.2% | -84.67M▼ 219.8% | -58.02M▲ 31.5% | -81.14M▼ 39.9% | -83.44M▼ 2.8% | -116.62M▼ 39.8% |
| Pretax Margin % | - | - | -64.76% | -71.59% | -601.87% | - | - | -3674.15% | -1824.51% |
| Income Tax | 0 | 0 | 0 | 35K | 15K | 10K | 27K | 141K | 637K |
| Effective Tax Rate % | 0% | 0% | 0% | -0.13% | -0.02% | -0.02% | -0.03% | -0.17% | -0.55% |
| Net Income | -20.24M▲ 0% | -19.17M▲ 5.3% | -18.75M▲ 2.2% | -26.51M▼ 41.4% | -84.69M▼ 219.4% | -58.03M▲ 31.5% | -81.17M▼ 39.9% | -83.58M▼ 3.0% | -117.26M▼ 40.3% |
| Net Margin % | - | - | -64.76% | -71.68% | -601.98% | - | - | -3680.36% | -1834.48% |
| Net Income Growth % | - | 5.28% | 2.2% | -41.42% | -219.44% | 31.47% | -39.87% | -2.97% | -40.29% |
| Net Income (Continuing) | -20.24M | -19.17M | -18.75M | -26.51M | -84.69M | -58.03M | -81.17M | -83.58M | -117.26M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 3.77M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -32.27▲ 0% | -30.57▲ 5.3% | -30.39▲ 0.6% | -41.10▼ 35.2% | -4.94▲ 88.0% | -227.42▼ 4503.6% | -53.08▲ 76.7% | -9.37▲ 82.3% | -12.48▼ 33.2% |
| EPS Growth % | - | 5.27% | 0.59% | -35.24% | 87.98% | -4503.64% | 76.66% | 82.35% | -33.19% |
| EPS (Basic) | -32.27 | -30.57 | -30.39 | -41.10 | -4.94 | -227.58 | -53.09 | -9.37 | -12.48 |
| Diluted Shares Outstanding | 627.09K | 627.09K | 616.89K | 645.06K | 4.45M | 255.17K | 1.53M | 8.92M | 9.4M |
| Basic Shares Outstanding | 627.09K | 627.09K | 616.89K | 645.06K | 4.45M | 255K | 1.53M | 8.92M | 9.4M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
KRRO Balance Sheet
Korro Bio, Inc. (KRRO) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 17.95M | 42.94M | 221.35M | 225.06M | 134.75M | 57.08M | 172.73M | 131.53M | 82.37M |
| Cash & Short-Term Investments | 17.94M | 42.19M | 217.35M | 220.34M | 130.71M | 55.85M | 166.15M | 126.09M | 75.16M |
| Cash Only | 17.94M | 42.19M | 200.16M | 220.34M | 79.64M | 36.94M | 166.15M | 55.64M | 21.82M |
| Short-Term Investments | 0 | 0 | 17.2M | 0 | 51.07M | 18.91M | 0 | 70.45M | 53.33M |
| Accounts Receivable | 0 | 161K | 805K | 340K | 144K | 0 | 0 | 1.7M | 969K |
| Days Sales Outstanding | - | - | 10.15 | 3.36 | 3.74 | - | - | 272.58 | 55.33 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 15K | 587K | 1M | 1.83M | 1.04M | -376K | 3.56M | 3.74M | 6.25M |
| Total Non-Current Assets | 1.83M | 1.61M | 1.86M | 39.66M | 50.61M | 16.66M | 48.94M | 94.71M | 31.13M |
| Property, Plant & Equipment | 1.73M | 1.51M | 1.76M | 37.84M | 36.87M | 11.89M | 42.81M | 51.55M | 16.22M |
| Fixed Asset Turnover | - | - | 16.43x | 0.98x | 0.38x | - | - | 0.04x | 0.39x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 1.82M | 13.42M | 4.54M | 0 | 36.96M | 0 |
| Other Non-Current Assets | 103K | 100K | 101K | 0 | 320K | 228K | 6.12M | 6.2M | 14.91M |
| Total Assets | 19.79M▲ 0% | 44.55M▲ 125.1% | 223.22M▲ 401.1% | 264.72M▲ 18.6% | 185.36M▼ 30.0% | 73.74M▼ 60.2% | 221.66M▲ 200.6% | 226.24M▲ 2.1% | 113.51M▼ 49.8% |
| Asset Turnover | - | - | 0.13x | 0.14x | 0.08x | - | - | 0.01x | 0.06x |
| Asset Growth % | - | 125.14% | 401.07% | 18.59% | -29.98% | -60.22% | 200.59% | 2.06% | -49.83% |
| Total Current Liabilities | 2.23M | 3.77M | 52.78M | 26.63M | 11.43M | 8.7M | 19.48M | 14.96M | 11.94M |
| Accounts Payable | 994K | 1.86M | 1.22M | 5.51M | 2.75M | 2.6M | 7.28M | 3.99M | 1.65M |
| Days Payables Outstanding | 683.26 | 1.04K | 26.46 | 1.27K | 261.14 | - | - | - | 140.8 |
| Short-Term Debt | 0 | 0 | 0 | 397K | 2.58M | 2.92M | 0 | 0 | 2.67M |
| Deferred Revenue (Current) | 0 | 0 | 48.15M | 14.07M | 0 | 0 | 0 | 3.51M | 7.83M |
| Other Current Liabilities | 479K | 876K | 3.41M | 1.6M | 1.73M | 551K | 395K | 4.05M | -221K |
| Current Ratio | 8.07x | 11.38x | 4.19x | 8.45x | 11.79x | 6.56x | 8.87x | 8.79x | 6.90x |
| Quick Ratio | 8.07x | 11.38x | 4.19x | 8.45x | 11.79x | 6.56x | 8.87x | 8.79x | 6.90x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 47.2M | 85.28M | 3.08M | 45.6M | 43.1M | 164.07M | 32.27M | 50.87M | 50.13M |
| Long-Term Debt | 46.69M | 84.94M | 0 | 15M | 14.17M | 163.86M | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 30.6M | 28.85M | 209K | 31.22M | 43.48M | 40.81M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 510K | 349K | 180K | 0 | 87K | 0 | 1.05M | 1.47M | 1.48M |
| Total Liabilities | 49.43M | 89.06M | 55.86M | 72.23M | 54.53M | 172.77M | 51.75M | 65.83M | 62.07M |
| Total Debt | 46.69M | 84.94M | 0 | 45.99M | 45.6M | 166.99M | 33.21M | 44.77M | 43.49M |
| Net Debt | 28.76M | 42.75M | -200.16M | -174.35M | -34.04M | 130.06M | -132.94M | -10.88M | 21.66M |
| Debt / Equity | - | - | - | 0.24x | 0.35x | - | 0.20x | 0.28x | 0.85x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - |
| Interest Coverage | -115.30x | -179.83x | - | - | -109.83x | -499.98x | - | - | - |
| Total Equity | -29.64M▲ 0% | -44.51M▼ 50.2% | 167.36M▲ 476.0% | 192.49M▲ 15.0% | 130.82M▼ 32.0% | -99.03M▼ 175.7% | 169.91M▲ 271.6% | 160.41M▼ 5.6% | 51.44M▼ 67.9% |
| Equity Growth % | - | -50.16% | 476.01% | 15.02% | -32.04% | -175.7% | 271.57% | -5.59% | -67.93% |
| Book Value per Share | -47.27 | -70.98 | 271.29 | 298.41 | 29.42 | -388.09 | 111.10 | 17.98 | 5.47 |
| Total Shareholders' Equity | -29.64M | -48.28M | 167.36M | 192.49M | 130.82M | -99.03M | 169.91M | 160.41M | 51.44M |
| Common Stock | 13K | 14K | 31K | 34K | 35K | 0 | 8K | 9K | 9K |
| Retained Earnings | -29.92M | -49.09M | -68.89M | -95.4M | -180.09M | -101.83M | -183M | -266.59M | -383.85M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 54K | 27K | -62K | -5K | 0 | 268K | 212K |
| Minority Interest | 0 | 3.77M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
KRRO Cash Flow Statement
Korro Bio, Inc. (KRRO) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -14.61M | -17.02M | 34.22M | -45.19M | -32.09M | -53.65M | -67.28M | -60.07M | -78.56M |
| Operating CF Margin % | - | - | 118.2% | -122.18% | -228.13% | - | - | -2645.27% | -1229.05% |
| Operating CF Growth % | - | -16.49% | 300.98% | -232.07% | 28.98% | -67.15% | -25.42% | 10.71% | -30.77% |
| Net Income | -20.24M | -19.17M | -18.75M | -10.23M | -21.96M | -58.03M | -81.17M | -83.58M | -117.26M |
| Depreciation & Amortization | 531K | 654K | 813K | 1.58M | 1.59M | 2.51M | 3.63M | 3.56M | 3.79M |
| Stock-Based Compensation | 0 | 0 | 0 | 0 | 807K | 1.14M | 2.38M | 4.46M | 7.66M |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | -145K | 0 | 0 | 0 |
| Other Non-Cash Items | 5.88M | 1.98M | 3.5M | -6.3M | -13.44M | 1.51M | 3.6M | 1.89M | 31.68M |
| Working Capital Changes | 276K | 819K | 48.65M | -30.24M | 904K | -633K | 4.28M | 13.59M | -4.43M |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -1.7M | 727K |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 0 | 0 | -644K | 4.29M | 56K | 1.75M | 3.1M | -1.34M | -2.31M |
| Cash from Investing | -1.86M | 3.34M | -18.26M | 10.4M | -39.5M | 11.06M | 11.16M | -123.35M | 43.99M |
| Capital Expenditures | -1.86M | -436K | -1.06M | -6.67M | -4.45M | -5.21M | -7.84M | -17.9M | -518K |
| CapEx % of Revenue | - | - | 3.68% | 18.04% | 31.61% | - | - | 788.29% | 8.1% |
| Acquisitions | 0 | 3.77M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | 13K | 0 | 0 | 0 | 0 |
| Cash from Financing | 27.98M | 37.94M | 142.01M | 56.69M | 115.94M | 18K | 187.76M | 69.36M | 685K |
| Debt Issued (Net) | 0 | 5M | 0 | 15M | 0 | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 27.98M | 32.94M | 142.01M | 41.69M | 115.95M | 62K | 162.71M | 67.39M | 685K |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 0 | 0 | 0 | 0 | -2K | -44K | 25.05M | 1.97M | 0 |
| Net Change in Cash | 11.5M▲ 0% | 24.25M▲ 110.9% | 157.97M▲ 551.4% | 20.18M▼ 87.2% | 44.35M▲ 119.7% | -42.57M▼ 196.0% | 131.64M▲ 409.3% | -114.07M▼ 186.7% | -33.82M▲ 70.4% |
| Free Cash Flow | -16.48M▲ 0% | -17.46M▼ 6.0% | 33.15M▲ 289.9% | -51.86M▼ 256.4% | -36.54M▲ 29.5% | -58.86M▼ 61.1% | -75.12M▼ 27.6% | -77.98M▼ 3.8% | -79.08M▼ 1.4% |
| FCF Margin % | - | - | 114.52% | -140.22% | -259.75% | - | - | -3433.55% | -1237.16% |
| FCF Growth % | - | -5.97% | 289.87% | -256.43% | 29.54% | -61.07% | -27.63% | -3.8% | -1.41% |
| FCF per Share | -26.28 | -27.84 | 53.74 | -80.39 | -8.22 | -230.65 | -49.12 | -8.74 | -8.42 |
| FCF Conversion (FCF/Net Income) | 0.72x | 0.89x | -1.83x | 1.70x | 0.38x | 0.92x | 0.83x | 0.72x | 0.67x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 11K | 27K | 141K | 0 |
KRRO Key Ratios
Korro Bio, Inc. (KRRO) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | - | -30.52% | -14.73% | -52.39% | -365.06% | -229.04% | -50.61% | -110.7% |
| Return on Invested Capital (ROIC) | - | - | - | -113.88% | -109.67% | -69.24% | -186.49% | -73.92% | -58.85% |
| Gross Margin | - | - | 41.92% | 95.73% | 72.7% | - | - | 100% | 33.04% |
| Net Margin | - | - | -64.76% | -71.68% | -601.98% | - | - | -3680.36% | -1834.48% |
| Debt / Equity | - | - | - | 0.24x | 0.35x | - | 0.20x | 0.28x | 0.85x |
| Interest Coverage | -115.30x | -179.83x | - | - | -109.83x | -499.98x | - | - | - |
| FCF Conversion | 0.72x | 0.89x | -1.83x | 1.70x | 0.38x | 0.92x | 0.83x | 0.72x | 0.67x |
| Revenue Growth | - | - | - | 27.76% | -61.96% | -100% | - | - | 181.46% |
KRRO SEC Filings & Documents
Korro Bio, Inc. (KRRO) SEC filings — annual & quarterly reports (10-K, 10-Q)
KRRO Frequently Asked Questions
Korro Bio, Inc. (KRRO) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Korro Bio, Inc. (KRRO) reported $6.4M in revenue for fiscal year 2025.
Korro Bio, Inc. (KRRO) grew revenue by 181.5% over the past year. This is strong growth.
Korro Bio, Inc. (KRRO) reported a net loss of $117.3M for fiscal year 2025.
Dividend & Returns
Korro Bio, Inc. (KRRO) has a return on equity (ROE) of -110.7%. Negative ROE indicates the company is unprofitable.
Korro Bio, Inc. (KRRO) had negative free cash flow of $79.1M in fiscal year 2025, likely due to heavy capital investments.
Explore More KRRO
Korro Bio, Inc. (KRRO) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates